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Abstract
Manganese (Mn) is an essential element that is incorporated in various metabolic pathways and enzyme structures. On the other hand, a range 
of adverse effects has been described in association with Mn overexposure. Mn is a well-known neurotoxic agent in mammals. Renal injury is 
another adverse effect associated with Mn intoxication. No precise mechanism for Mn nephrotoxicity has been identified so far. The current study 
was designed to evaluate the potential mechanisms of Mn-induced renal injury. Rats were treated with Mn (20 and 40 mg/mL, respectively, in 
drinking water) for 30 consecutive days. Markers of oxidative stress, as well as several mitochondrial indices, were assessed in the kidney tissue. 
Renal injury was evident in Mn-treated animals, as judged by a significant increase in serum BUN and creatinine. Moreover, urinalysis revealed a 
significant increase in urine glucose, phosphate, and protein in Mn-treated rats. Kidney histopathological alterations, including tubular atrophy, 
interstitial inflammation, and necrosis, were also detected in Mn-treated animals. Biomarkers of oxidative stress, including an increment in reac-
tive oxygen species (ROS), lipid peroxidation, and oxidized glutathione (GSSG), were detected in Mn-treated groups. On the other hand, kidney 
glutathione (GSH) stores and total antioxidant capacity were depleted in Mn groups. Mn exposure was associated with significant mitochon-
drial depolarization, decreased mitochondrial dehydrogenases activity, mitochondrial permeabilization, and depletion of adenosine tri-phosphate 
(ATP) content. These data highlight oxidative stress and mitochondrial impairment as potential mechanisms involved in Mn-induced renal injury.
Keywords: energy crisis; manganism; mitochondria; renal failure; serum electrolyte waste
Received: 23 April 2020; Accepted after Revision: 13 May 2020; Published: 09 June 2020
Author for correspondence: Reza Heidari and Leila Moezi, Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, 
 Shiraz, Iran. Fax: 07131242626, Tel: 07131242627-282. Emails: rezaheidari@hotmail.com; reidari@sums.ac.ir; moezil@sums.ac.ir. ORCID: 
https://orcid.org/0000-0002-7038-9838.
How to cite: Niknahad AM, et al. Manganese-Induced Nephrotoxicity is Mediated through Oxidative Stress and Mitochondrial Impairment. 
J Ren Hepat Disord. 2020;4(2):1–10.
Doi: http://dx.doi.org/10.15586/jrenhep.2020.66
Copyright: Niknahad AM, et al.
License: This open access article is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). http://creativecommons.org/
P   U   B   L   I   C   A   T   I   O   N   S
 CODON
Introduction
Manganese (Mn) is a trace element incorporated in sev-
eral metabolic pathways and in the structures of some vital 
enzymes (1, 2). However, it has also been found that Mn 
overexposure is associated with several deleterious adverse 
effects, such as neurotoxicity (1, 3–5). Renal injury and dis-
turbances of serum electrolytes are the other adverse effects 
associated with Mn overexposure (6–8). There is no precise 
mechanism for Mn-induced nephrotoxicity.
The mechanism of Mn neurotoxicity is widely investi-
gated (9). It has been found that Mn-induced oxidative stress 
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and 40 ± 2% relative humidity). Animals had free access to 
tap water and a commercial rodents chow diet (RoyanFeed®, 
Isfahan, Iran). All procedures on experimental animals were 
performed in compliance with the ethical guidelines approved 
by the Shiraz University of Medical Sciences ethics commit-
tee (#95-01-36-11290). Animals were allotted to three groups 
(n = 8 in each group), and treated as follows: (i) Control 
(vehicle-treated); (ii) MnCl2 (20 mg/mL in drinking water); 
and (iii) MnCl2 (40 mg/mL in drinking water). Animals were 
treated for 42 consecutive days. On day 43, rats were anes-
thetized, and serum and kidney tissue samples were collected.
Sample collection
Animals were anesthetized (Thiopental 80 mg/kg, i.p). Blood 
was collected from the abdominal aorta and transferred to 
standard tubes (VACUSERA®, Serum gel, and clot activator 
tubes) for serum preparation. The kidney tissue was washed 
in ice-cooled (4°C) normal saline and used for further assess-
ments. Kidney weight index (WI) was determined as WI = 
[wet weight of organ (g)/body weight (g)] × 100. 
Reactive oxygen species
Renal tissue ROS levels were measured using dichlorofluo-
rescein diacetate (DCFH-DA) as a fluorescent probe (19). 
Briefly, 10 μL of DCFH-DA (10 μM final concentration) 
was added to 990 μL of tissue homogenate (10% w: v in KCl 
buffer). Samples were incubated for 15 min at 37°C in the 
dark. Finally, the DCF fluorescence intensity was assessed 
using a fluorimeter (FLUOstar Omega®, BMG LABTECH, 
 Germany; λexcit = 485 nm and λem = 525 nm) (19).
Renal tissue lipid peroxidation
Thiobarbituric acid reactive substances (TBARS) in renal 
tissue were measured as an index of lipid peroxidation in the 
renal tissue (12, 20). Briefly, renal tissue (500 mg) was homog-
enized in ice-cooled KCl buffer (1.15% w: v; 4°C). Then, 
500 µL of tissue homogenate was added to a reaction mixture 
consisting of 1 mL TBA (0.375%, w: v), 1 mL trichloroacetic 
acid (20% w: v), and meta-phosphoric acid (3 mL f 1% w: 
v solution, pH = 2) (21). The mixture was incubated in a water 
bath (100°C) for 45 min (22). Then, 4 mL of n-butanol was 
added and vortexed (1 min). Finally, samples were centrifuged 
(17,000 × g for 10 min) and the absorbance of the developed 
color in upper phase (n-butanol) was measured at λ = 532 nm 
(EPOCH® plate reader, Highland Park, USA) (21).
Renal tissue and mitochondria glutathione content
Renal glutathione levels (oxidized and reduced; GSSG and 
GSH) were measured by the HPLC method (23). The HPLC 
plays a central role in the adverse effects of this metal on the 
nervous system (9–12). It has been reported that Mn accu-
mulates in cellular mitochondria through calcium (Ca2+) 
channels (2). Hence, cellular mitochondria are critical tar-
gets for Mn cytotoxicity. Mitochondrial depolarization, 
mitochondria swelling, increased mitochondria-mediated 
reactive oxygen species (ROS) formation, and mitochondria- 
mediated cell death have been reported in different experi-
mental models that investigated Mn neurotoxicity (9–13).
Renal tissue contains numerous mitochondria, the proper 
functioning of which guarantee appropriate energy (ATP) 
level required for the reabsorption process of chemicals 
(14–16). The mechanism of nephrotoxicity induced by sev-
eral xenobiotics relies on mitochondrial impairment and 
mitochondria- mediated cell death (17). Oxidative stress 
and mitochondrial injury are two mechanistically related 
events (18). Hence, mitochondrial impairment could deteri-
orate oxidative stress and vice versa.
As already mentioned, there is no precise mechanism for 
Mn-induced renal injury. The current study was designed to 
evaluate the role of oxidative stress and mitochondrial impair-
ment in the pathogenesis of Mn nephrotoxicity. Rats were 
exposed to Mn for 30 consecutive days. Several biomarkers in 
serum and urine, as well as histopathological alterations and 
oxidative stress markers in renal tissue, were evaluated. More-
over, kidney tissue mitochondria were isolated and assessed.
Materials and Methods
Reagents
3-[4,5dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide 
(MTT), iodoacetic acid, potassium hydroxide, bovine serum 
albumin (BSA), methanol high performance liquid chromatog-
raphy (HPLC) grade, 3-(N-morpholino) propane sulfonic acid 
(MOPS), 4,2Hydroxyethyl,1-piperazineethanesulfonic acid 
(HEPES), dimethyl sulfoxide (DMSO), thiobarbituric acid 
(TBA), glacial acetic acid, glutathione (GSH), malondialde-
hyde (MDA), 2′,7′ Dichlorofluorescein diacetate (DCFH-DA), 
acetonitrile HPLC grade, ethylene glycol-bis (2-aminoethyl 
ether)-N, N, N′, N′-tetraacetic acid (EGTA), sucrose, dith-
iothreitol (DTT), sodium chloride, and Rhodamine 123 were 
obtained from Sigma Chemical Co. (St. Louis, MO, USA). 
Manganese chloride (MnCl2), trichloroacetic acid (TCA), and 
hydroxymethyl aminomethane hydrochloride (Tris-HCl) were 
purchased from Merck (Darmstadt, Germany).
Animals and treatments
Mature male Sprague–Dawley rats (200–250 g, live weight; 
n = 24) were obtained from Shiraz University of Medicine, 
Shiraz, Iran. Rats were maintained under standard conditions 
(22–24°C; 12:12 h, photo schedule; appropriate ventilation; 
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(pH = 7.4; 4°C). Afterward, 50 µL of tissue homogenate was 
added to 900 µL of the FRAP reagent and incubated in the 
dark (37°C, 5 min). The intensity of the resultant blue color 
was measured at λ = 593 nm using an EPOCH plate reader 
(BioTek® Instruments, Highland Park, US) (27).
Histopathological assessment
For histopathological evaluations, renal specimens were fixed 
in a buffered formalin solution prepared from NaH2PO4 
(0.4% w: v), Na2HPO4 (0.64% w: v), and formaldehyde 
(10%) in double-distilled water (pH = 7.4). Paraffin-embed-
ded tissue specimens were cut (5 µm) using a microtome and 
stained with hematoxylin and eosin. Kidney histopathologi-
cal changes were evaluated using a light microscope (Olym-
pus BX41; Olympus Optical Co. Ltd, Japan).
Renal and serum Mn levels
Serum and kidney Mn levels were measured using an 
inductively coupled plasma mass spectrometry (ICP-MS) 
method (28). Briefly, serum (500 µL) and kidney tissue sam-
ples (500 µL of 10% w: v tissue homogenate) were treated 
with 100 µL of nitric acid (HNO3; 2.5% w: v) and centrifuged 
(17,000 g, 30 min). The supernatants were collected and used 
for Mn determination (28).
Kidney mitochondria isolation
Rats’ kidneys were washed (NaCl 0.9% w: v, 4°C) and minced 
in the ice-cold isolation buffer containing 0.5 mM EGTA, 2 
mM HEPES, 220 mM sucrose, 70 mM mannitol, and BSA 
(0.1% w: v) (pH = 7.4). Minced tissue was transported into 
fresh isolation buffer (5 mL buffer: 1 g tissue) and homog-
enized. Kidney mitochondria were isolated based on the 
differential centrifugation method (29). For this purpose, 
unbroken cells and nuclei were pelleted at the first round of 
centrifugation (1000 g for 10 min at 4°C). Afterward, the 
supernatant was centrifuged at 10,000 g (10 min at 4°C) to 
pellet the mitochondria fraction (brown-colored). The sec-
ond centrifugation step was repeated at least thrice using a 
fresh buffer medium. Finally, mitochondrial pellets were 
resuspended in a buffer (5 mL buffer/g tissue) containing 70 
mM mannitol, 220 mM sucrose, and 2 mM HEPES (pH = 
7.4). The mitochondria fractions used to measure mitochon-
drial permeabilization and mitochondrial depolarization 
were suspended in mitochondria permeabilization buffer (65 
mM KCl, 10 mM HEPES, 125 mM Sucrose, pH = 7.2) and 
depolarization assay buffer (220 mM Sucrose, 10 mM KCl, 
68 mM Mannitol, 5 mM KH2PO4, 2 mM MgCl2, 50 μM 
EGTA, and 10 mM HEPES, pH = 7.2) (29). Sample pro-
tein concentrations were determined based on the  Bradford 
method to standardize the obtained data.
system consisted of an NH2 column as the stationary phase 
(25 cm, Bischoff chromatography, Leonberg, Germany) (24). 
The mobile phases consisted of buffer A (Water: Methanol; 
1: 4 v: v) and buffer B (Acetate buffer: Buffer A; 1: 4 v: v), 
and a gradient method with a steady increase of buffer B to 
95% in 25 min (24). The flow rate of the mentioned mobile 
phase was 1 mL/min, and the UV detector (UV) detector 
was set at λ = 254 nm. Tissue samples were homogenized in 
Tris-HCl buffer (250 mM; pH = 7.4; 4°C), and 500 µL of 
TCA (50% w: v) was added. Isolated mitochondria (1 mL, 
1 mg protein/mL) were also treated with 100 µL of TCA 50% 
w: v. Samples were mixed well, incubated on ice (10 min), 
and centrifuged (17,000 g, 30 min, 4°C). Afterward, 1 mL of 
the supernatant was collected in 5 mL tubes and 300 µL of 
the NaOH: NaHCO3 (2 M: 2 M) solution was added. Then, 
100 µL of iodoacetic acid (1.5% w: v in deionized water) 
was added, and samples were incubated for 1 h (4°C, in the 
dark). Afterward, 2, 4-dinitrofluorobenzene (DNFB, 500 µL 
of 1.5% w: v in absolute ethanol) was added and mixed well. 
Samples were incubated in the dark (25°C, 24 h). Finally, 
samples were centrifuged (17,000 g, 30 min) and injected 
(25 µL) into the described HPLC system (23).
Protein carbonylation
The oxidative damage of kidney tissue proteins was 
assessed based on the reaction with dinitrophenyl hydrazine 
(DNPH)  (25). Briefly, 1 mL of the tissue homogenate (10% 
w: v) was treated with 100 µL of the triton X-100 (0.1% w: v) 
and centrifuged (10 min, 700 g, 4°C). Then, 500 µL aliquots 
of the resulting supernatant were treated with 300 µL of 
DNPH (10 mM in HCl). Samples were then incubated for 1 h 
(25°C, vortexing every 10 min). Afterward, 100 µL of trichlo-
roacetic acid (20% w: v) was added and centrifuged (12,000 g, 
5 min) (26). The pellet was washed three times with ethanol: 
ethyl acetate (1 mL of 1: 1 v: v solution). Finally, the precipi-
tate was re-dissolved in guanidine hydrochloride solution (600 
µL of 6 M solution), and the absorbance at λ = 370 nm was 
measured (EPOCH® plate reader, Highland Park, USA) (25).
Ferric reducing antioxidant power
The ferric reducing antioxidant power (FRAP) of kidney tis-
sue was measured (27). The FRAP assay measures change 
in the absorbance at λ = 593 nm due to the formation of a 
blue-colored ferrous (Fe2+)-4, 6-tripyridyl-s-triazine (TPTZ) 
complex from the colorless oxidized ferric form (Fe3+) by the 
action of tissue electron-donating antioxidants. The work-
ing FRAP solution was freshly prepared by mixing 25  mL 
of acetate buffer (300 mmol/L; pH = 3.6) with 2.5  mL of 
TPTZ ( 10 mmol/L in 40 mmol/L HCl) and 2.5 mL of fer-
ric chloride (FeCl2 , 20 mmol/L). Tissue samples (200 mg) 
were homogenized in 5 mL of 250 mM Tris-HCl buffer 
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Mitochondrial dehydrogenases activity
A colorimetric technique based on the production of purple 
formazan crystals from the 3-(4, 5-dimethylthiazol-2-yl)-2, 
5-diphenyltetrazolium bromide was used for the estima-
tion of mitochondrial dehydrogenases activity (30). Briefly, 
a mitochondrial suspension (0.5 mg protein/mL) was incu-
bated with 40 µL of MTT (0.4% w: v) and incubated in 
the dark (37°C, 30 min). Samples were centrifuged (15,000 
g, 15 min), and the pellet was dissolved in dimethyl sulfox-
ide (DMSO; 1000 µL). The optical density (OD) at λ = 570 
nm was measured with an EPOCH® plate reader (Highland 
Park, USA) (30).
Mitochondrial ATP levels
Based on a previously reported protocol, mitochondrial ATP 
level was assessed by HPLC (31, 32). Briefly, isolated mito-
chondria (1 mg protein/mL) were mixed with 100 µL ice-
cooled meta-phosphoric acid solution (50% w: v, 4°C) and 
centrifuged (30 min, 17,000 g, 4°C). Afterward, the superna-
tant (100 µL) was treated with 15 µL of ice-cooled potassium 
hydroxide solution (KOH, 1 M). Samples were centrifuged 
(30 min, 17,000 g, 4°C) again, and 25 µL of the supernatant 
was injected into an HPLC system composed of an LC-18 
column (µ-Bondapak, 25 cm). The mobile phase was com-
posed of potassium hydrogen phosphate mono-basic (100 
mM KH2PO4, pH = 7 adjusted with KOH), acetonitrile 
(2.5% v: v), and tetrabutylammonium hydroxide (1 mM). 
The flow rate was 1 mL/min, and the UV detector was set at 
λ = 254 nm (31).
Mitochondrial depolarization
Mitochondrial uptake of the cationic dye rhodamine 123 was 
applied for the evaluation of mitochondrial depolarization 
(33, 34). Rhodamine 123 accumulates in the mitochondrial 
matrix by facilitated diffusion. When the mitochondrion is 
depolarized, there is no facilitated diffusion, and the amount 
of rhodamine 123 in the supernatant will be increased (35). 
In the current investigation, the mitochondrial fractions 
(0.5 mg protein/mL; in the depolarization assay buffer) were 
incubated with 10 µM of rhodamine 123 (30 min, 37°C, in 
the dark). Afterward, samples were centrifuged (15,000 g, 
10 min, 4°C) and the fluorescence intensity of the superna-
tant was monitored with a fluorimeter (FLUOstar Omega®; 
BMG, Germany; λexcit = 485 nm and λem = 525 nm) (33, 36).
Mitochondrial permeabilization and swelling
Mitochondrial swelling was estimated by analyzing the 
changes in optical density at λ = 540 nm (34, 37). Briefly, 
isolated mitochondria (0.5 mg protein/ml) were suspended 
in the mitochondria permeabilization buffer (65 mM KCl, 
125 mM Sucrose, 10 mM HEPES, pH = 7.2), and the absor-
bance was monitored (30°C, during 30 min of incubation) 
using an EPOCH® plate reader (Highland Park, USA). 
An increase in mitochondrial swelling is associated with a 
decrease in absorbance. The results are reported as maximal 
mitochondrial swelling amplitude (ΔOD 540 nm) (37).
Lipid peroxidation in kidney mitochondria
TBARS were measured in isolated kidney mitochondria. Pre-
vious studies mentioned that sucrose interferes with the lipid 
peroxidation test in isolated mitochondria preparations (37). 
Therefore, mitochondria preparations were washed once 
(to remove sucrose) in ice-cooled MOPS-KCl buffer (100 
mM KCl, 50 mM MOPS, 4°C, pH = 7.4). For this purpose, 
isolated kidney mitochondria were suspended in 5  mL of 
MOPS-KCl buffer and centrifuged (15,000 g, 4°C, 20 min). 
The pellet was re-suspended in MOPS-KCl buffer and used 
for TBARs assay. The mitochondrial suspension (1 mg pro-
tein/mL) was mixed with 1 mL of a solution containing tri-
chloroacetic acid (15% w: v), HCl (0.24 N), TBA (0.375% w: 
v), and Trolox (500 µM). Samples were heated for 15 min at 
100°C (37). Then n-butanol (1 mL) was added and vortexed 
(5 min). Samples were centrifuged (15,000 g, 10 min), and 
the absorbance of the n-butanol phase (upper phase) was 
measured (EPOCH® plate reader, Highland Park, USA, λ = 
532 nm) (37).
Statistical methods
Data are represented as mean ± SD. Data analysis was 
accomplished by the one-way analysis of variance (ANOVA) 
and the Tukey’s multiple comparison test as the post hoc 
test. A P < 0.05 was considered as a statistically significant 
difference.
Results
Animal weight gain was significantly lower in the Mn-treated 
group (40 mg/mL) in comparison with control rats 
 (Figure 1A). The kidney WI was also significantly lower in 
Mn 40 mg/mL group (Figure 1A). Serum and kidney tissue 
Mn levels were also significantly higher in Mn-treated ani-
mals (Figure 1B).
Significant deterioration in serum biochemical measure-
ments indicates renal injury in Mn-treated rats (Table 1). Signs 
of hypophosphatemia were evident in the Mn group (Table 1). 
On the other hand, serum BUN and creatinine levels were sig-
nificantly higher in Mn-exposed animals (20 and 40 mg/mL) 
(Table 1). Significant elevation in urine protein, alkaline phos-
phatase (ALP), γ-glutamyl transferase (γ-GT), and glucose 
level was also detected in Mn-treated rats (Table 2).
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Figure 1. Effect of manganese treatment (20 and 40 mg/mL for 30 consecutive days) on animals’ weight gain, renal weight index 
(Panel A), and serum and kidney tissue manganese (Mn) (Panel B).
Data are shown as mean ± SD (n = 8).
#Indicates significantly different as compared with the control group (P < 0.05).
Table 1. Serum biochemical measurements in manganese (Mn)-treated rats.
Control Mn
20 mg/mL
Mn
40 mg/mL
Ca2+ (mg/dL) 5.0 ± 0.20 4.9 ± 0.40 5.0 ± 0.50
K+ (mmol/L) 5.5 ± 0.40 4.6 ± 0.32 4.5 ± 0.50
Na+ (mmol/L) 84.0 ± 4.00 76 ± 3.00 71.0 ± 2.00
Glucose (mg/dL) 113.0 ± 9.00 105 ± 5.00 97.0 ± 11.00
Phosphate (mg/dL) 3.4 ± 0.40 2.33 ± 0.40 2.1 ± 0.11#
Total protein (mg/dL) 6.8 ± 0.44 7.1 ± 0.9 6.9 ± 0.30
Blood urea nitrogen (mg/dL) 43.0 ± 2.00 66.0 ± 5.00# 68 ± 4.00#
Creatinine (mg/dL) 0.3 ± 0.02 0.6 ± 0.03# 0.8 ± 0.03#
Data are represented as mean ± SD (n = 8).
#Indicates significantly different as compared with the control group (P < 0.01).
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Table 2. Urinalysis of manganese (Mn)-treated animals.
Control Mn
20 mg/mL
Mn
40 mg/mL
Protein (mg/dL) 0.4 ± 0.1 1.1 ± 0.10# 1.2 ± 0.20#
ALP (U/L) 2122 ± 115 2380 ± 193 2670 ± 390#
γ-GT (U/L) 2569 ± 166 3134 ± 113 3897 ± 575#
Glucose (mg/dL) 80.0 ± 4.00 96.0 ± 19.00 132.0 ± 3.00#
Data are represented as mean ± SD (n = 8).
ALP: alkaline phosphatase; γ-GT: γ-glutamyl transferase.
#Indicates significantly different as compared with the control group (P 
< 0.01).
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Figure 2. Markers of oxidative stress in the kidney tissue of manganese-treated rats.
Data are given as mean ± SD (n = 8).
Asterisks indicate significantly different from the control group (* P < 0.05, *** P < 0.001).
Significant ROS formation, lipid peroxidation, and protein 
carbonylation were detected in Mn groups (Figure 2). More-
over, kidney tissue GSH was depleted, and the GSSG level 
was significantly increased in Mn-exposed animals  (Figure 2). 
Tissue antioxidant capacity was also dose-dependently 
decreased in the kidneys of Mn-treated rats  (Figure 2).
Several mitochondrial indices were assessed in the kidney 
tissue of  Mn-treated rats (Figure 3). It was found that Mn 
exposure significantly decreased mitochondrial dehydroge-
nases activity and ATP levels in a dose-dependent manner 
(Figure 3). Moreover, a significant increment of  mitochon-
drial depolarization and swelling was detected in the kid-
ney mitochondria of  Mn-treated animals (Figure 3). Lipid 
peroxidation was also dose-dependently increased in the 
kidney mitochondria isolated from Mn-exposed animals 
(Figure 3).
Significant interstitial inflammation and tubular atrophy 
were evident in the kidneys of Mn 20 and 40 mg/mL groups 
(Figure 4 and Table 3). Moreover, Mn 40 mg/mL caused 
renal tissue necrosis (Figure 4 and Table 3).
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Figure 3. Markers of mitochondrial impairment in the kidneys of manganese-treated animals.
Data are presented as mean ± SD (n = 8).
*** Significantly different from the control group (P < 0.001).
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Figure 4. Kidney tissue histopathological alterations in manganese-exposed animals. Hematoxylin and eosin staining. The grades 
of histopathological changes are given in Table 3.
Table 3. Renal tissue histopathological alterations in manganese-exposed rats.
Interstitial inflammation Tubular atrophy Necrosis
Control − − −
Manganese 20 mg/mL + + +
Manganese 40 mg/mL ++ ++ +++
+: Mild; ++: Moderate; and +++: Severe histopathological alterations.
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Discussion
Mn is a trace element that plays a fundamental role in sev-
eral metabolic pathways and enzyme structures (2). However, 
overexposure to this metal is associated with a wide range 
of adverse effects, including renal injury (6–8, 38). Acute 
tubular necrosis, proteinuria, oliguria, and significant eleva-
tion in serum creatinine levels have been reported in human 
cases of Mn-induced nephrotoxicity (6, 38–40). No precise 
mechanism for Mn-induced nephrotoxicity has been identi-
fied so far. In the current investigation, it was found that Mn 
caused significant oxidative stress as well as mitochondrial 
impairment in the kidney tissue. The results might help in 
the development of therapeutic options against renal failure 
and serum electrolyte imbalance observed in Mn-intoxicated 
patients (6, 38–41).
Neurotoxicity is a well-described adverse effect of Mn (9, 
13, 42–45). Oxidative stress and its consequences, such as 
disruption of biomembrane lipids and protein carbonyla-
tion, seem to play a fundamental role in Mn-induced toxicity 
in different organs such as the brain (9, 13, 42–45). Severe 
elevation in brain tissue ROS level and lipid peroxidation 
has been documented in Mn-induced neurotoxicity (9, 13, 
42–45). Moreover, it has been found that brain tissue anti-
oxidant systems are hampered upon Mn overexposure (9, 13, 
42–45). The mechanism(s) of nephrotoxicity induced by Mn 
is less understood. Previous studies mentioned the occur-
rence of oxidative stress in the renal tissue of Mn-exposed 
animals (7). Mn-induced oxidative stress could affect several 
cellular targets, including biomembrane lipids, proteins, as 
well as deoxyribonucleic acid (7). In the current study, sig-
nificant ROS formation, protein carbonylation, lipid perox-
idation, and depletion of kidney tissue antioxidant capacity 
was evident in Mn-exposed rats. These results are consistent 
with previous investigations indicating Mn-induced oxida-
tive stress in the kidney (7). Moreover, we found that kidney 
mitochondria could also be affected by Mn overexposure.
Cellular mitochondria are critical targets affected by 
Mn.  (13). It has been found that Mn is accumulated in the 
mitochondrial matrix through Ca2+ channels (13). Induction 
of mitochondrial permeabilization, enhancement of mitochon-
dria-facilitated ROS formation, a decrease of cellular ATP lev-
els, and mitochondria-mediated cell death and apoptosis are 
associated with Mn-induced mitochondrial impairment (13).
Mitochondria play a fundamental role in kidney tissue 
(14–16). The reabsorption of chemicals (e.g., amino acids, 
glucose, and minerals) from nephrons to the bloodstream 
is an energy-dependent activity (14–16). Kidney tissue con-
tains numerous mitochondria, the proper functioning of 
which guarantee enough ATP required for the reabsorption 
process of chemicals (14–16). Hence, Mn-induced mito-
chondrial impairment leads to an energy crisis and defect 
in the reabsorption of many chemicals in the renal tubules. 
Consequently, serum electrolyte disturbances could occur. 
Cellular mitochondria are also important sites of ROS 
production (18). It has been repeatedly reported that xeno-
biotics-induced mitochondrial impairment could facilitate 
mitochondria-mediated ROS formation (18). Based on the 
data obtained from the current study, we might be able to 
speculate that Mn-induced mitotoxicity could serve as a 
major cause of oxidative stress in the renal tissue.
Conclusion
Collectively, our results indicate the fundamental role of 
oxidative stress and mitochondrial impairment in the patho-
genesis of Mn-induced renal injury. Therefore, targeting cel-
lular mitochondria might serve as a therapeutic point against 
Mn-induced nephrotoxicity.
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